

H. S. Yathirajan,^a S. Bindya,^a
T. V. Sreevidya,^b B. Narayana^b
and Michael Bolte^{c*}^aDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India, ^bDepartment of Chemistry, Mangalore University, Mangalagangotri 574 199, India, and ^cInstitut für Anorganische Chemie, J. W. Goethe-Universität Frankfurt, Max-von-Laue-Strasse 7, 60438 Frankfurt/Main, GermanyCorrespondence e-mail:
bolte@chemie.uni-frankfurt.de

Key indicators

Single-crystal X-ray study
 $T = 173$ K
Mean $\sigma(\text{C}-\text{C}) = 0.002$ Å
 R factor = 0.040
 wR factor = 0.106
Data-to-parameter ratio = 13.9For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


A second polymorph of carvedilol

A second polymorph of the title compound [systematic name: 1-(9*H*-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol], $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_4$, is described. The other polymorph [Chen, Zeng, Yu & Xu (1998). *Jiegou Huaxue (Chin. J. Struct. Chem.)*, **17**, 325–328] also crystallizes in the space group $P2_1/c$, but differs in two torsion angles of the chain connecting the aromatic residues. On the other hand, the hydrogen-bond patterns of the two polymorphs are rather similar.

Received 2 January 2007
Accepted 4 January 2007

Comment

Carvedilol, $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_4$, is a non-selective β -adrenergic blocking agent with α_1 -blocking activity indicated for the treatment of congestive heart failure (CHF). It is the first β -blocker labelled in the United States especially for the treatment of heart failure of ischemic or cardiomyopathic origin with significant antioxidant activity (Ruffolo *et al.*, 1990; Feuerstein *et al.*, 1995; Zeng *et al.*, 2003).



The crystal structure of carvedilol was described in space group $P2_1/c$ (Chen *et al.*, 1998). We now report a second polymorph of carvedilol, (I) (Fig. 1), in the same space group, which differs in two key torsion angles. The bond lengths and angles for (I) can be regarded as normal (Cambridge Structural Database, Version 5.27, November 2005, updated August 2006; Mogul Version 1.1; Allen, 2002). The structure of (I) shows several significant differences from the already known (Chen *et al.*, 1998) polymorph, (II). Although both structures are monoclinic and crystallize in the same space group, the cell parameters are completely different [for (II), $a = 9.094$ (1) Å, $b = 12.754$ (1) Å, $c = 18.330$ (2) Å and $\beta = 97.36$ (1)°]. The molecular conformations of (I) and (II) are totally different, but a closer look reveals that only two torsion angles are in fact responsible for this difference (Table 1). Whereas the conformation about the C2–C3 bond is antiperiplanar in (I), it is synclinal in (II), and the conformation about O8–C81 is anticlinal in (I) but synclinal in (II). A least-squares fit (Fig. 2) of the matching torsion angles (*i.e.* fitting the chain from C2 to




Figure 1
The molecular structure of (I), showing 50% probability displacement ellipsoids (arbitrary spheres for the H atoms).




Figure 2
Least-squares overlap of the main backbones of (I) (full bonds) and (II) (open bonds).

O8; r.m.s. deviation = 0.134 Å) shows the similarities and differences of (I) and (II).

Nevertheless, the two classical hydrogen bonds in (I) are also present in (II) (Tables 2 and 3). The carbazole N atom forms an intermolecular hydrogen bond to the methoxy O atom O87 and the hydroxyl group forms an intermolecular hydrogen bond to the amino N atom. However, whereas it is a 2_1 screw axis that generates the second molecule for the $N_c-H\cdots O$ (c = carbazole) hydrogen bond in (I) and (II), the symmetry operation for generating the second molecule for the $O-H\cdots N$ hydrogen bond is a c -glide plane in (I), but an inversion centre in (II). The amino H atom has close contacts

to the hydroxyl O atom and the ether O atom (Tables 2 and 3), but the $H\cdots O$ distances are rather long and the $N-H\cdots O$ angles are rather small.

Experimental

Carvedilol was obtained as a gift sample from Cadila Pharmaceuticals, Gujarat, India. X-ray quality crystals of (I) were obtained from toluene by slow evaporation (m.p. 385–387 K).

Crystal data

| | |
|--------------------------------|---|
| $C_{24}H_{26}N_2O_4$ | $Z = 4$ |
| $M_r = 406.47$ | $D_x = 1.275 \text{ Mg m}^{-3}$ |
| Monoclinic, $P2_1/c$ | Mo $K\alpha$ radiation |
| $a = 15.5414 (14) \text{ \AA}$ | $\mu = 0.09 \text{ mm}^{-1}$ |
| $b = 15.2050 (12) \text{ \AA}$ | $T = 173 (2) \text{ K}$ |
| $c = 9.1174 (8) \text{ \AA}$ | Block, colourless |
| $\beta = 100.730 (7)^\circ$ | $0.36 \times 0.33 \times 0.32 \text{ mm}$ |
| $V = 2116.8 (3) \text{ \AA}^3$ | |

Data collection

| | |
|--|--|
| Stoe IPDS-II two-circle diffractometer | 3956 independent reflections |
| ω scans | 3060 reflections with $I > 2\sigma(I)$ |
| Absorption correction: none | $R_{\text{int}} = 0.034$ |
| 12521 measured reflections | $\theta_{\text{max}} = 25.7^\circ$ |

Refinement

| | |
|--|--|
| Refinement on F^2 | $w = 1/[\sigma^2(F_o^2) + (0.0583P)^2 + 0.3118P]$ |
| $R[F^2 > 2\sigma(F^2)] = 0.040$ | where $P = (F_o^2 + 2F_c^2)/3$ |
| $wR(F^2) = 0.106$ | $(\Delta/\sigma)_{\text{max}} < 0.001$ |
| $S = 1.03$ | $\Delta\rho_{\text{max}} = 0.29 \text{ e \AA}^{-3}$ |
| 3956 reflections | $\Delta\rho_{\text{min}} = -0.21 \text{ e \AA}^{-3}$ |
| 285 parameters | Extinction correction: <i>SHELXL97</i> |
| H atoms treated by a mixture of independent and constrained refinement | Extinction coefficient: 0.0127 (14) |

Table 1

Selected torsion angles ($^\circ$) for (I) and (II).

| | (I) | (II) |
|---------------|--------------|--------|
| C12–C11–O1–C2 | 164.14 (11) | –175.2 |
| C11–O1–C2–C3 | –173.50 (11) | 177.2 |
| O1–C2–C3–C4 | 170.44 (11) | 59.2 |
| C2–C3–C4–N5 | 178.21 (12) | 175.0 |
| C4–N5–C6–C7 | 169.95 (12) | 167.3 |
| C6–C7–O8–C81 | 161.69 (13) | 159.8 |
| C7–O8–C81–C82 | 129.41 (15) | –150.7 |

Table 2

Hydrogen-bond geometry (Å, $^\circ$).

| $D-H\cdots A$ | $D-H$ | $H\cdots A$ | $D\cdots A$ | $D-H\cdots A$ |
|----------------------------------|------------|-------------|-------------|---------------|
| O31–H31 \cdots N5 ⁱ | 0.92 (2) | 2.09 (2) | 2.9633 (16) | 158 (2) |
| N1–H1 \cdots O87 ⁱⁱ | 0.94 (2) | 2.11 (2) | 3.0336 (19) | 167.4 (18) |
| N5–H5 \cdots O8 | 0.910 (19) | 2.456 (18) | 2.8619 (17) | 107.3 (13) |
| N5–H5 \cdots O31 | 0.910 (19) | 2.443 (17) | 2.8198 (17) | 105.0 (13) |

Symmetry codes: (i) $x, -y + \frac{1}{2}, z + \frac{1}{2}$; (ii) $-x + 1, y + \frac{1}{2}, -z + \frac{1}{2}$.

Table 3
Hydrogen bond parameters for (II).

| $D-H\cdots A$ | $D-H$ | $H\cdots A$ | $D\cdots A$ | $D-H\cdots A$ |
|----------------------------------|-------|-------------|-------------|---------------|
| $O-H\cdots N^{iii}$ | 1.14 | 1.73 | 2.837 | 173 |
| $N^{carbazole}-H\cdots O^{iv}$ | 0.90 | 2.35 | 3.193 | 156 |
| $N^{amino}-H\cdots O^{ether}$ | 0.90 | 2.48 | 2.828 | 103 |
| $N^{amino}-H\cdots O^{hydroxyl}$ | 0.90 | 2.70 | 2.872 | 92 |

The geometrical values for the $O-H\cdots N$ bond were taken from the original publication. The other values were determined by us with H atoms placed in calculated positions. Symmetry codes: (iii) $1-x, -y, -z$; (iv) $1-x, \frac{1}{2}+y, \frac{1}{2}-z$.

The H atoms were found in a difference map. Those bonded to C were relocated in idealized locations ($C-H = 0.95-1.00 \text{ \AA}$) and refined as riding with $U_{iso}(H) = 1.2U_{eq}(C)$ or $1.5U_{eq}(\text{methyl C})$. The positions and U_{iso} values for the H atoms bonded to N and O were freely refined.

Data collection: *X-AREA* (Stoe & Cie, 2001); cell refinement: *X-AREA*; data reduction: *X-AREA*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics:

PLATON (Spek, 2003) and *XP* in *SHELXTL-Plus* (Sheldrick, 1991); software used to prepare material for publication: *PLATON* and *SHELXL97*.

SB thanks the University of Mysore and TVS thanks Mangalore University for research facilities.

References

- Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
 Chen, W.-M., Zeng, L.-M., Yu, K.-B. & Xu, J.-H. (1998). *Jiegou Huaxue (Chin. J. Struct. Chem.)*, **17**, 325–328.
 Feuerstein, G. Z., Poste, G. & Ruffolo, R. R. (1995). *Drugs Today*, **31**, 307–326.
 Ruffolo, R. R. Jr, Gellai, M., Heible, J. P., Willette, R. N. & Nichols, A. J. (1990). *Eur. J. Clin. Pharmacol.* **38** (Suppl 2), 82–88.
 Sheldrick, G. M. (1991). *SHELXTL-Plus*. Release 4.1. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
 Stoe & Cie (2001). *X-AREA*. Stoe & Cie, Darmstadt, Germany.
 Zeng, H., Liu, X. & Zhao, H. (2003). *J. Huazhong Univ. Sci. Technol. Med. Sci.* **23**, 127–130.